Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON trials. J of Skin. 2024;8(6):s492. doi:10.25251/skin.8.supp.492